HC Wainwright Weighs in on FibroBiologics Q1 Earnings

FibroBiologics, Inc. (NASDAQ:FBLG) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of FibroBiologics in a research report issued to clients and investors on Tuesday, April 1st. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($0.11) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2029 earnings at ($0.59) EPS.

A number of other analysts also recently commented on the stock. D. Boral Capital restated a “buy” rating and set a $16.00 price target on shares of FibroBiologics in a research report on Tuesday. Rodman & Renshaw assumed coverage on FibroBiologics in a research report on Thursday, December 12th. They issued a “buy” rating and a $12.00 target price for the company. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $13.00.

FibroBiologics Stock Performance

Shares of NASDAQ FBLG opened at $0.86 on Wednesday. The firm’s 50-day simple moving average is $1.28 and its 200 day simple moving average is $2.14. FibroBiologics has a fifty-two week low of $0.86 and a fifty-two week high of $13.59.

Institutional Investors Weigh In On FibroBiologics

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its holdings in FibroBiologics by 90.0% during the 3rd quarter. Geode Capital Management LLC now owns 599,760 shares of the company’s stock worth $1,854,000 after buying an additional 284,047 shares during the period. State Street Corp raised its holdings in shares of FibroBiologics by 26.5% during the third quarter. State Street Corp now owns 475,837 shares of the company’s stock valued at $1,470,000 after acquiring an additional 99,789 shares during the period. Cerity Partners LLC lifted its position in shares of FibroBiologics by 49.9% in the 4th quarter. Cerity Partners LLC now owns 78,101 shares of the company’s stock valued at $156,000 after acquiring an additional 26,001 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in FibroBiologics by 5.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 69,732 shares of the company’s stock worth $215,000 after purchasing an additional 3,451 shares during the period. Finally, Jane Street Group LLC grew its position in FibroBiologics by 415.3% during the 4th quarter. Jane Street Group LLC now owns 61,074 shares of the company’s stock worth $122,000 after purchasing an additional 49,222 shares in the last quarter.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.